Understanding LYNOZYFIC™ (linvoseltamab-gcpt)

In July 2025, the FDA approved the use of Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM) who have received at least 4 prior lines of therapy. This booklet explains how Lynozyfic works, its dose and schedule, clinical trial experience with Lynozyfic, the precautions and possible side effects for you to discuss with your doctor, as well as the support programs for patients who are prescribed Lynozyfic.